The mechanism in more detail
GHK-Cu is a small peptide (glycine-histidine-lysine) that occurs naturally in the body, chelating a copper ion to form the active GHK-Cu complex; levels decline with age. Rather than acting through a single defined receptor, it has been described across a body of in-vitro, animal and human research as working through several overlapping pathways: modulating both the synthesis and controlled breakdown of collagen, elastin and other extracellular-matrix components, influencing the balance of matrix-remodelling enzymes and their natural inhibitors, attracting immune and endothelial cells to sites of injury, promoting new blood-vessel formation, and showing antioxidant and anti-inflammatory activity. No single confirmed cell-surface receptor for this activity has been established in the literature reviewed.
Separately, large-scale gene-expression studies from the peptide’s originating research group report that GHK can alter expression of several thousand human genes associated with tissue repair and inflammation, described by that group as shifting gene activity toward a pattern more typical of younger tissue. This is plausible mechanistic data, but it has not been independently replicated outside the originating research group, and should be read as laboratory-level gene-expression research rather than a demonstrated clinical mechanism.
It is worth noting, for clarity, that the “GH” in GHK-Cu refers to its glycine-histidine amino-acid sequence and has no connection to growth hormone; the name is coincidental, not indicative of growth-hormone-axis activity.
Almost all human clinical evidence for GHK-Cu concerns topical, cosmetic application, such as facial or scalp creams and serums, rather than wound healing directly or systemic administration. Cross-species animal research, in dogs, rats, mice and pigs, has studied topical, subcutaneous and intraperitoneal wound-healing applications, but no controlled human wound-healing trial has been identified to date, and no controlled human data exists for injectable or systemic use. These are genuine evidence gaps, not incidental caveats: the topical-cosmetic and injectable-or-systemic uses of GHK-Cu sit under separate regulatory frameworks, detailed in the Regulatory Status section of this page.